We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics and advanced technologies.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Behind the science
Discover how we're getting ahead
Harnessing tumour DNA to detect cancer recurrence earlier
Antibiotic resistance: now’s the time to prevent the next pandemic
Getting ahead of COPD exacerbations using new tech could save lives
The logic of biologic medicines: advancing care for people with immune-mediated conditions
Eosinophils could be holding the missing link between symptoms, diagnosis and treatment
Time for a change: personalising asthma treatment
Unlocking the power of the immune system to get ahead of hepatitis B
Tackling tomorrow’s health challenges today
How vaccine science can help tackle antimicrobial resistance
The 40 year fight against HIV
Life at GSK
How we help people thrive
Diversity, equity and inclusion
Positively impacting society and the planet
Pricing and access
We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.
Global health and health security
We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.
Diversity, equity and inclusion
Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.
We are working towards a net zero impact on climate and a net positive impact on nature by 2030, across our full value chain.
Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.
In the spotlight
GSK on social
#Gonorrhea is the second most common sexually transmitted bacterial infection and a high priority pathogen for @WHO due to growing resistance to antibiotics. That’s why we are researching new solutions.Twitter @GSK Dec 06
In 2011, GSK launched Trust in Science in Latin America. The public-private partnership model focuses on peer-to-peer scientific collaboration. Earlier this week, the first licensing agreement was signed out of this public-private partnership model. @CONICETDialoga @FilmusDanielTwitter @GSK Dec 05
For Andy, a life-changing diagnosis led to a complete shift in career. Now, as Workplace Adjustments Service Director at GSK, he helps support employees needing workplace adaptions to carry out their day-to-day work reach their full potential. Hear his story 👇 #IDPwDD 4vTwitter @GSK Dec 03
To celebrate the #InternationalDayOfPersonsWithDisabilities, we’re proud to be talking about our partnership with @Valuable500 to drive action for disability inclusion. Learn more from Caroline Casey, CEO of Valuable 500 and GSK's Sally Jackson 👇 #IDPwDD tLTwitter @GSK Dec 03
Twitter @GSK Dec 02
#News for #investors and #media: Today we announced positive topline results evaluating our treatment plus standard-of-care chemotherapy in patients with primary advanced or recurrent #endometrialcancer. Click to learn moreTwitter @GSK Dec 02
Today is #WorldAIDSDay2022 This day is an opportunity for people across the globe to challenge #HIV stigma and discrimination, to show support for people living with HIV and remember those who have died from AIDS-related illnesses worldwide. #RockTheRibbonTwitter @GSK Dec 01
New global survey highlights the need for people living with lupus and their healthcare providers to prioritise discussions around organ damage prevention. Learn more: gsk.to/3gJLbmOTwitter @GSK Nov 30
Emerging evidence suggests that climate change could be worsening #AntiMicrobialResistance. Another sign of how climate and health are closely connected. We're working hard to reduce our climate impact and to find new tools to help get ahead of #AMR, together. twitter.com/wellcometrust/…Twitter @GSK Nov 30
Organ damage impacts many people living with #lupus within 5 years of diagnosis. A new global survey of healthcare professionals suggests conversations with patients about #SLE organ damage risk may not be happening early enough in course of disease. gsk.to/3EMv4wzTwitter @GSK Nov 29